ArticleRMD open2025
Serum immunoreactivity to neurofilament-medium shows high sensitivity and specificity in patients with Behçet disease.
Article in RMD open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesBehçet disease (BD) is a complex vasculitis with both autoimmune and autoinflammatory features. Despite specific clinical features, no laboratory tests are available for the diagnosis of BD. We recently found that BD sera exhibited immunoreactivity against neurofilament medium protein (NF-M). This study aimed to replicate this finding in an independent cohort and to assess the specificity and sensitivity of NF-M immunoreactivity in serum samples obtained from BD, systemic lupus erythematosus (SLE), multiple sclerosis (MS), psoriatic arthritis (PsA) and non-Behçet uveitis (NBU) patients as well as healthy donors.
methodsSerum samples from 76 patients (33 BD, 16 MS, 15 SLE, 9 PsA and 3 NBU) and 22 healthy donors (totalling 98 sera) were analysed. Mouse brain tissue sections were immunolabelled with the sera and examined using confocal microscopy.
results97% (32/33) of BD patient sera exhibited a distinct fine filamentous staining pattern consistent with NF-M protein immunolabelling in axons, while sera from healthy controls and patients with SLE, MS, PsA and NBU showed no similar staining. Conversely, MS patient sera displayed a thick filamentous staining pattern attributed to oligodendrocytes and their myelin-forming processes. SLE patient sera intensely labelled all cell nuclei, conforming to immunoreactivity against nuclear antigens.
conclusionsThese findings reveal the ubiquitous presence of NF-M immunoreactivity, reportedly cross-reacting with bacterial heat shock protein 65, in BD sera. This common and specific immunoreactivity may serve as a valuable tool for diagnosing BD. Additionally, the data confirm the unique potential of connective tissue-poor brain sections for identifying sero-immunoreactivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.